Retrospective Study Evaluating IGF1R And p95HER2 as Prognostic Factors in Non Small Cell Lung Cancer (NSCLC)
September 8, 2022 updated by: Armando Santoro, MD
Retrospective Study Evaluating IGF1R And p95HER2 as Prognostic Factors in Radically Resected Non Small Cell Lung Cancer
Aim of the study is to evaluated the role of IGF1R and p95HER2 on prognosis in radically resected non small cell lung cancer patients
The primary objective is to correlate the expression of IGF1R and p95HER2 with survival.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
454
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Milan
-
Rozzano, Milan, Italy, 20089
- Istituto Clinco Humanitas
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Radically resected non small cell lung cancer patients
Description
Inclusion Criteria:
- Radically resected non small cell lung cancer patients with tumor tissue available
Exclusion Criteria:
- Tumor tissue not available
- Clinical data not available
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
1
Radically resected Non small cell lung cancer patients in stage I-III
|
Protein expression by immunohistochemistry and immunofluorescence
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Association of different biomarkers with survival
Time Frame: At the end of enrollment
|
At the end of enrollment
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Association of a specific biomarker with patient's characteristics
Time Frame: At the end of enrollment
|
At the end of enrollment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2007
Primary Completion (Actual)
December 1, 2009
Study Completion (Actual)
December 1, 2009
Study Registration Dates
First Submitted
September 30, 2008
First Submitted That Met QC Criteria
September 30, 2008
First Posted (Estimate)
October 1, 2008
Study Record Updates
Last Update Posted (Actual)
September 10, 2022
Last Update Submitted That Met QC Criteria
September 8, 2022
Last Verified
September 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ONC/OSS-02/2007
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.